HOME >> BIOLOGY >> NEWS
Unique two-part macroemulsion offers new approach to cleaning up contaminated aquifers

taminate hundreds of thousands of gallons of groundwater," Pennell noted.

Established remediation techniques (pump and treat) often rely on pumping large amounts of contaminated water out of the ground, flushing the pollutants with it. However, these techniques require large volumes of water and may need to be operated for many years. The cost of treating the contaminated water and the time required make this approach very expensive -- and serves only to contain the contaminated groundwater.

The approach developed by the Georgia Tech team could allow remediation engineers to directly address pollution mass removal, with recovery rates exceeding 90 percent.

"Our approach is to aggressively treat the source zone where the actual spill occurred and remove the compound, then separate and treat or recycle it above ground," Pennell explained. "We are trying to remove the long-term source of groundwater contamination in a manner that will produce the most results for the least cost. It's generally not economically feasible to treat the entire aquifer."

One issue that all such solvent remediation efforts must address is containing the problem. Because these chlorinated compounds are heavier than water, removal efforts can inadvertently drive them deeper into the ground if underground water supplies lack natural boundaries such as impermeable clay or bedrock.

To keep the dense nonaqueous phase liquids (DNAPL) from flowing deeper into the earth, engineers have injected alcohols such as n-butanol into the pollution mass to lower its density. They have also injected surfactant chemicals food or pharmaceutical quality agents similar to those used in whipped toppings and shampoos which reduce the interfacial tension to separate the solvent from soil particles.

The patent-pending technique developed by Pennell and collaborators C. Andrew Ramsburg, Tohren C.G. Kibbey and Kim F. Hayes combines both approaches, making the
'"/>

Contact: John Toon
john.toon@edi.gatech.edu
404-894-6986
Georgia Institute of Technology Research News
17-Sep-2003


Page: 1 2 3

Related biology news :

1. Unique partnership between UH, FDA opens path for scientific exchange
2. Unique fleet of underwater vehicles to gather elusive environmental data
3. Unique feeding behavior discovered for snakes
4. Unique population of muscle stem cells found in mice
5. Unique social system found in famous Tsavo lions
6. Unique national park for orchids to be declared in Africa
7. Unique genetic alteration in presenilin 1 gene predisposes some Caribbean Hispanics to early-onset Alzheimers disease
8. Unique UNC study confirms suspected worldwide epidemic of childhood obesity
9. Scientists find just how discriminating a worm can be: Unique system of overlapping odor sensors discovered
10. Unique study reveals new details on how genes are transcribed
11. Unique international conference to focus on effectiveness, safety of medicinal herbs

Post Your Comments:
(Date:10/22/2014)... Medicine® scientists helps explain how bipolar disorder affects the ... therapies to treat the mental illness. , Scientists ... method recognized with the 2014 Nobel Prize in ... from mice with bipolar-like behaviors. In the synapses (where ... structures with concentrated levels of ANK3 -- the gene ...
(Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst firm ... half of the world,s population will have a chip-based ... Europe . Asia , ... market accounting for more than 60% of all National ... Acuity,s report  -- "The Global National eID ...
(Date:10/19/2014)... in India over the last 30 years contributed ... growth during that time, according to a new ... Change ., "Energy access is fundamental to development: ... including education, communication, and health," says IIASA researcher ... increased energy access is widely agreed to be ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2
(Date:10/25/2014)... , October 24, 2014 ... Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... Thursday, October 23, 2014, ended on a positive note ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... WriteResult, LLC – a premier provider of ... a team of researchers from Yale University’s School of ... to provide electronic questionnaire data collection through use of ... in May, aims to evaluate the impact of a ... and participation in urban agriculture to impact their consumption ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
Cached News: